SCYNEXIS Showcases SCY-247 at IDWeek 2024
SCYNEXIS, Inc. (NASDAQ: SCYX), a leading biotechnology company focused on addressing drug-resistant and challenging infections, is set to present new and compelling preclinical data on its second-generation antifungal agent, SCY-247, at the highly anticipated IDWeek event in Los Angeles. This event takes place from October 16 to October 19, 2024, offering an opportunity for healthcare professionals, researchers, and industry experts to engage with cutting-edge research.
Presentation Details for SCY-247
The presentations will feature both an oral and a poster session, allowing for comprehensive discussions on the efficacy and pharmacokinetics of SCY-247. Below are the key details:
Oral Presentation Highlights
Title: Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections
Session: Mycology Matters: Insights into Fungal Infections
Date/Time: October 17, 2024, at 10:45 AM PDT
Location: Los Angeles Convention Center, Room 403 B
Presenter: David A. Angulo, M.D., President and CEO of SCYNEXIS
Poster Presentation Insights
Title: SCY-247: A Second-generation IV/Oral Triterpenoid Antifungal with Extensive Tissue Distribution and Pharmacokinetics, and Low Drug-Drug Interaction Potential
Session: New Drug Development
Date/Time: October 18, 2024, from 12:15 PM to 1:30 PM PDT
Location: Los Angeles Convention Center, Halls JK
Presenter: David A. Angulo, M.D., President and CEO of SCYNEXIS
The Promise of SCY-247
SCY-247 represents a significant advancement in the antifungal space, focusing on a novel class of glucan synthase inhibitors known as triterpenoids. This innovative antifungal compound is currently in the pre-IND development stage and aims to address the growing challenge of antimicrobial resistance (AMR) in systemic fungal infections, which can lead to high mortality rates. The triterpenoid class is noteworthy as it is the first new class of antifungal compounds approved since 2001, combining existing glucan synthase inhibition with the flexibility of both oral and intravenous (IV) formulations.
Early studies have demonstrated SCY-247’s broad-spectrum activity against a range of multidrug-resistant fungal pathogens, which is critical in a landscape where treatment options are limited. Additionally, SCYNEXIS is optimistic that the FDA will grant SCY-247 qualified designations for both the IV and oral formulations, acknowledging its potential to make a significant impact in treating these difficult infections.
About SCYNEXIS, Inc.
Founded to innovate the way patients are treated for severe and resistant infections, SCYNEXIS, Inc. (NASDAQ: SCYX) continues to develop its proprietary antifungal platform known as “fungerps.” One of the company's key achievements includes the licensing of ibrexafungerp to GSK, which became the first representative of this class. The FDA approved ibrexafungerp tablets, branded as BREXAFEMME, in June 2021 for vulvovaginal candidiasis, followed by a second indication to reduce recurrent cases. SCYNEXIS remains committed to addressing unmet medical needs with its innovative antifungal agents, including SCY-247, which is currently in preclinical development.
Contact Information for Inquiries
For further information or inquiries, please contact:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
Email: ikoffler@lifesciadvisors.com
Frequently Asked Questions
What is SCY-247?
SCY-247 is a second-generation antifungal compound developed by SCYNEXIS, designed to target drug-resistant fungal infections.
When and where will SCYNEXIS present data on SCY-247?
SCYNEXIS will present findings at IDWeek 2024 in Los Angeles on October 17 and 18.
Who is presenting the SCY-247 data?
The presentations will be given by David A. Angulo, M.D., the President and CEO of SCYNEXIS.
What are the potential benefits of SCY-247?
It offers broad-spectrum antifungal activity against multidrug-resistant organisms and has low drug-drug interaction potential.
How does SCYNEXIS aim to combat antimicrobial resistance?
By developing innovative antifungal therapies like SCY-247, SCYNEXIS seeks to address the rising challenge of antimicrobial resistance in fungal infections.
